Market capitalization | $291.54m |
Enterprise Value | $-90.82m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.54 |
EV/Sales (TTM) EV/Sales | -2.24 |
P/S ratio (TTM) P/S ratio | 7.19 |
P/B ratio (TTM) P/B ratio | 0.76 |
Revenue (TTM) Revenue | $40.56m |
EBIT (operating result TTM) EBIT | $-220.55m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
11 Analysts have issued a Zentalis Pharmaceuticals Inc forecast:
11 Analysts have issued a Zentalis Pharmaceuticals Inc forecast:
Dec '23 |
+/-
%
|
||
Net Profit | -292 -292 |
23%
23%
|
|
Depreciation and Amortization | 1.39 1.39 |
3%
3%
|
|
Stock Compensation | 55 55 |
17%
17%
|
|
Operating Cash Flow | -208 -208 |
27%
27%
|
|
Investments | 0.58 0.58 |
77%
77%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -208 -208 |
25%
25%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Zentalis Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers in the United States. Its lead product candidate is the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase I/II clinical trial for the treatment of breast cancer. The company is also developing ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2 for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor that is in Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals, LLC was founded in 2014 and is based in New York, New York.
Head office | United States |
CEO | Kimberly Blackwell |
Employees | 168 |
Founded | 2014 |
Website | www.zentalis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.